Trial Profile
Effects of vorapaxar on QT/QTC interval in volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Apr 2012
Price :
$35
*
At a glance
- Drugs Vorapaxar (Primary) ; Moxifloxacin
- Indications Acute coronary syndromes; Arterial thrombosis; Bacterial infections
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme
- 18 Apr 2012 Results presented at the 113th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
- 18 Apr 2012 New trial record